SAN FRANCISCO — Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation rates and fewer ED visits per exacerbation at 104 ...

The phase 3 MATINEE trial (NCT04133909) provided additional context for where mepolizumab may be most useful. 2 This trial randomized 804 patients with a history of frequent exacerbations and ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe exacerbations in a year, according to results published in The New England ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

The researchers found that the annualized rate of moderate or severe exacerbations was significantly lower with mepolizumab than placebo (0.80 vs 1.01 events per year; rate ratio, 0.79).

The randomized, double-blind, placebo-controlled phase 3 study (ClinicalTrials.gov Identifier: NCT04133909) evaluated the safety and efficacy of mepolizumab, an interleukin-5 antagonist monoclonal ...

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), drugmaker GSK announced on Thursday. Labeling for the interleukin-5 (IL ...

In the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma trial, mepolizumab reduced asthma exacerbations and led to improvements in several measures of asthma control.Mepolizumab ...

Mepolizumab Reduces Need for Oral Steroids in Severe Asthma — Some adults on the IL-5 antibody were able to stop taking systemic steroids by Ed Susman , Contributing Writer, MedPage Today March ...

Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options First anti-IL5 biologic to give healthcare professionals choice of how and where their patients receive treatment ...

Mepolizumab works by blocking the production of eosinophils and has been shown to reduce the frequency of asthma exacerbations and the need for steroids in two small proof-of-concept studies.

To the Editor: Bel et al. (Sept. 25 issue)1 report that treatment with mepolizumab, a monoclonal antibody against interleukin-5, allowed a modest reduction in the maintenance dose of oral glucocor ...